Biogen's haemophilia B drug Alprolix gets FDA approval

Biogen Idec has received approval from the US Food and Drug Administration (FDA) for its long-acting haemophilia B treatment Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein].
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news